SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is surging as investors react to the company's recent international expansion into Macau and positive analyst coverage, driving intense speculation about a potential short squeeze. The community is actively debating the significance of upcoming industry conferences and rumors regarding potential government funding, with many traders expressing frustration over coordinated selling pressure while remaining bullish on the firm's long-term pipeline.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is facing intense scrutiny and volatility as the company moves toward a reverse stock split, fueling deep divisions among retail investors. While some holders are speculating on a potential institutional rebound or a short squeeze, many are venting frustration over the lack of positive guidance and are actively positioning themselves to short the stock in anticipation of further downside.

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna Inc. is surging as investors capitalize on a growing natural gas supply crisis triggered by conflict in the Middle East and damage to critical energy infrastructure. Community sentiment remains highly bullish, with active discussions focusing on the stock's potential for a short squeeze, its role as a strategic European LNG supplier, and heavy retail accumulation as volume levels continue to climb.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing intense downward pressure and negative sentiment, with the community actively debating whether the stock's significant pullback represents a generational buying opportunity or a deeper structural decline. Investors are polarized over the company's heavy AI spending and the ongoing volatility, with many expressing frustration over the stock's persistent underperformance compared to the broader tech sector.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

The Fundrise Innovation Fund (VCX) is seeing intense volatility and record-high trading volume as retail investors react to its direct exposure to high-profile private AI firms like OpenAI, Anthropic, and SpaceX. While bullish sentiment is driven by the fund's unique access to these sought-after holdings, many market participants are actively debating the sustainability of its current market price compared to its intrinsic net asset value, frequently comparing the situation to previous low-float 'pump and dump' market events.

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008, and is headquartered in Newton, MA.

Karyopharm Therapeutics Inc

Karyopharm Therapeutics is trending as investors digest mixed results from its Phase 3 SENTRY trial in myelofibrosis, which met spleen volume reduction goals but missed on key symptom endpoints. Community discourse is highly polarized, with some highlighting the strong overall survival signal as a potential path for future regulatory success, while others express deep frustration over the company's financial runway and recent private placement deals.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is surging as heightened geopolitical tensions in the Middle East and physical damage to major LNG infrastructure in Qatar trigger fears of a severe, long-term global supply shortage. Investors are closely watching the stock for a potential squeeze, with the community highlighting the company's strategic position to capture market share and benefit from elevated spot prices amid ongoing industry disruption.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is currently surging on high volume driven by unconfirmed market rumors of potential M&A activity, fueling long-standing community speculation about a possible buyout. Investors are actively debating the credibility of these reports while highlighting the company's strong revenue growth and significant short interest as key factors that could intensify volatility.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is rallying as investors digest recent earnings, insider buying activity, and strategic AI partnerships, while the community remains divided over whether the stock is primed for a major short squeeze or vulnerable to further downside amid broader software sector volatility.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is trending as a highly speculative, low-cap meme coin that has polarized the community, with some traders touting its potential for explosive gains while others warn it is a classic pump-and-dump scheme. Discussion centers on its rapid price volatility, accessibility via DEX platforms, and ongoing debate over whether its current price action reflects genuine accumulation or manipulative tactics by top holders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

A Tesla car and pedestrians are caught in a storefront window while it drives down Broadway in downtown Los Angeles on January 8, 2026. (Genaro Molina/Los Angeles Times via Getty Images)

Elon Musk Once Dissolved Ad Team For Being ‘Generic’, But Fund Manager Urges Steve Jobs-Style Marketing For Higher Success

According to Gary Black, Apple owes its value to the best products coupled with the best marketing.

Equity

According to Gary Black, Apple owes its value to the best products coupled with the best marketing.


<ul class="summary-bullets"><li>If it materializes, it would be Gilead’s second major acquisition this year after it announced it would buy biotech Arcellx for $7.8 billion last month.</li><li>Ouro Medicine is developing drugs for autoimmune diseases such as lupus and rheumatoid arthritis.&nbsp;</li><li>Gilead is most known for its HIV drug franchise.</li></ul>Gilead Sciences (GILD) is reportedly looking to expand its offerings in the autoimmune disease segment with the acquisition of privately-held biotech Ouro Medicine for up to $2 billion.The Financial Times <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/81528c31-c735-41b7-b042-81a811a76877?syn-25a6b1a6=1">reported</a> on Monday that the company is looking to pay Ouro investors roughly $1.5 billion upfront in cash and at least an extra $500 million if certain clinical trial milestones are hit.As per the report, the talks are at an advanced stage and a deal could be announced in the coming days, though the terms might change. &nbsp;If it materializes, it would be Gilead’s second major acquisition this year after it announced it would buy biotech Arcellx for $7.8 billion last month in order to gain full access to a new multiple myeloma cell therapy.<h2 class="st-heading-2">Gilead’s Acquisition Approach</h2>“...we are carefully strengthening our early-stage pipeline to position Gilead well for the long term, typically investing about $1 billion annually in smaller licensing deals, partnerships, and acquisitions. Additionally, we are proactive and disciplined in our approach to later-stage acquisitions that support our strategic goals and add new growth opportunities,” the company said during its fourth quarter earnings call in February.“We're very ready, we're very proactive and disciplined, but we may not have the urgency of other companies in this sector, so we're gonna be disciplined around that. But I would say that we very much want to continue to add to our pipeline with appropriate, M&amp;A over the course of the coming years as well.”Gilead is most known for its HIV drug franchise. In 2025, the company reported a 6% in HIV product sales to $20.8 billion. The HIV product segment sales accounted for about 72% of the company’s overall product sales in the period.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around GILD stock fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume remained at ‘normal’ levels.<a href="https://stocktwits.com/symbol/GILD">GILD stock</a> has gained 29% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-estee-lauder-stock-down-today/cZ3mNcjRIKb">Why Is Estee Lauder Stock Down Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Gilead Sciences logo is displayed on a smartphone screen, with the company's branding visible in the background, on April 20, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Gilead Reportedly Eyes Yet Another Acquisition Worth $2B After Arcellx Deal

The Financial Times reported on Monday that the company is looking to pay Ouro investors roughly $1.5 billion upfront in cash and at least an extra $500 million if certain clinical trial milestones are hit.

<ul class="summary-bullets"><li>The deal could be announced as soon as Monday, according to The Financial Times.&nbsp;</li><li>According to a separate report from The Wall Street Journal, there is no guarantee that an agreement will be reached as the talks are continuing.</li><li>A potential deal could involve a mix of cash and stock, sources told WSJ.</li></ul>Cosmetic company Estée Lauder (EL) is reportedly nearing a deal to combine with Spanish beauty group Puig.The Financial Times <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/644a7f5c-ec48-49b8-bcb7-8ede2051ffcc?syn-25a6b1a6=1">reported</a> on Monday, citing sources familiar with the matter, that the company, behind brands including Clinique, M.A.C, Bobbi Brown Cosmetics and Le Labo, is looking to combine with the Spanish group that owns Jean Paul Gaultier, Dries Van Noten, Rabanne and Charlotte Tilbury, to create a company that would be valued at more than $40 billion. The deal could be announced as soon as Monday, the report added. &nbsp;Estee confirmed the ongoing discussions with Puig but noted in an emailed statement to Stocktwits that no final decision has been made and no deal has been inked. “Unless and until an agreement is signed between the companies, there can be no assurances regarding the deal or its terms,” the company said.&nbsp;EL shares traded 7% lower at the time of writing.<h2 class="st-heading-2">Potential Deal Details</h2>According to a separate <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/business/deals/estee-lauder-in-talks-to-acquire-spains-puig-to-create-global-beauty-giant-28c376d3">report</a> from The Wall Street Journal, citing sources familiar with the matter, a potential deal could involve a mix of cash and stock.Puig currently has a market value of about $10 billion. In 2025, the company reported solid net revenue growth, delivering €5,042 million ($5855.85 million) in 2025, up +7.8% like-for-like, at the top end of its outlook range.Earlier this month, the company also announced the separation of the roles of Chairman and CEO, and appointed Jose Manuel Albesa as CEO, while Marc Puig continues in the role of Executive Chairman.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around EL stock jumped from ‘bearish’ to ‘bullish’ territory, while message volume increased from ‘low’ to ‘normal’ levels.<a href="https://stocktwits.com/symbol/EL">EL stock</a> has gained about 18% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/insmed-new-lung-disease-study-data-win-for-company-says-analyst/cZ3mZljRIKG">Insmed’s New Lung Disease Study Data A Win For Company, Says Analyst</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.Exchange Rate: €1= $1.16 &nbsp;

Billboard of Estee lauder american parfume products at Magasin du Nord 24 Oct. 2011. (Photo by Francis Dean/Corbis via Getty Images) 

Why Is Estee Lauder Stock Down Today?

The Financial Times reported on Monday that Estée Lauder is looking to combine with the Spanish group Puig, to create a company that would be valued at more than $40 billion.

Is the Vanguard S&P 500 Index Fund ETF a Buy Now?

Key PointsThe Vanguard S&P 500 ETF is the largest ETF in the world...

Is the Vanguard S&P 500 ETF the Smartest Investment You Can Make Before March Ends?

Key PointsDividend, value, and defensive stocks have outperformed the S&P 500 in 2026...

<ul class="summary-bullets"><li>JPMorgan analysts raised their price target for FedEx to $432 from $424 while keeping a ‘Neutral’ rating, highlighting improved business execution in a tough operating environment.</li><li>Analysts at Wells Fargo stated they are impressed by the strength of FedEx’s business and noted that the company’s volumes and margins were strong.</li><li>Truist analysts said they are increasingly more positive on the stock given the company’s volume growth and continued cost execution.</li></ul>FedEx Corp. (FDX) has earned accolades from Wall Street following its beat-and-raise fiscal third-quarter (Q3) performance, with a slew of price target hikes pouring in.According to TheFly, analysts praised FedEx’s execution and operational efficiencies during the quarter.<a href="https://stocktwits.com/symbol/FDX">FedEx shares</a> were up nearly 8% in Friday’s pre-market trade.&nbsp;<h2 class="st-heading-2">Why Are Analysts Gung Ho?</h2>JPMorgan analysts raised their price target for FedEx to $432 from $424 while keeping a ‘Neutral’ rating. The firm said FedEx’s legacy business is benefiting from a “unique combination” of pricing and yield gains, alongside improved business execution in a tough operating environment.Analysts at Wells Fargo stated they are impressed by the strength of FedEx’s business, noting that the company’s volumes and margins were strong. The firm raised its price target for the FDX stock to $450 from $430 while keeping an ‘Overweight’ rating.Truist analysts said they are increasingly positive on FDX stock, given the company’s volume growth and continued cost execution. The firm stated that demand trends for FedEx appear stable in the fourth quarter (Q4), while its sales mix is shifting toward the business-to-business segment, which has higher margins. Truist hiked its price target for FedEx to $425 from $400 while keeping a ‘Buy’ rating.BofA analysts noted that, following FedEx’s strongest U.S. market share gains in 20 years, the logistics giant is showing good momentum in managing costs and transforming its network amid a volatile global trade backdrop. BofA hiked its price target for FedEx to $440 from $431, while keeping a ‘Buy’ rating.<h2 class="st-heading-2">FedEx Reports Strongest Market Share Gains In 20 Years</h2>FedEx&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fedex-dismisses-direct-impact-from-ongoing-tensions-in-middle-east/cZ3aCwSRIhA">reported</a> adjusted earnings per share (EPS) of $5.25 on revenue of $24 billion during Q3, while Wall Street analysts expected an adjusted EPS of $4.07 on revenue of $23.5 billion.The company stated that its Express segment’s operating results during the quarter were driven by higher U.S. domestic and International Priority package yields, continued cost savings from transformation initiatives, and increased U.S. domestic package volume.“Team FedEx delivered another quarter of strong financial results and excellent service for our customers, powered by disciplined operational execution, the resilience of our global network, and the accelerating impact of our advanced digital solutions,” said FedEx CEO Raj Subramaniam.The company also increased its revenue growth forecast for fiscal year 2026, stating that it expects topline growth of 6% to 6.5%, compared to its previous forecast of 5% to 6%.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory at the time of writing.<a href="https://stocktwits.com/symbol/FDX">FDX stock</a> is up 23% year-to-date and 44% over the past 12 months. The SPDR S&amp;P 500 ETF Trust (SPY) and the Vanguard S&amp;P 500 ETF (VOO) are up 16% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/iea-iran-war-oil-price-shock-advice-to-deal-wfh-cut-speeds-flights/cZ3X8SrRILB">As Oil Prices Surge Amid Iran War, IEA’s Advice Is Simple — Work From Home, Ease Off The Pedal, Skip That Flight</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

FedEx truck is seen on a street in Manhattan, New York City, United States of America on July 16th, 2024. (Photo by Beata Zawrzel/NurPhoto via Getty Images)

FedEx's Beat And Raise Q3 Earns Street Accolades As Price Target Hikes Pour In — Analysts Flag 'Unique Combination' Of Price And Yield Growth

According to TheFly, analysts praised FedEx’s execution and operational efficiencies during the quarter.

Should Vanguard 500 Index Fund ETF Shares (VOO) Be on Your Investing Radar?

<ul class="summary-bullets"><li>The company now expects 6.0% to 6.5% revenue growth rate year-over-year in fiscal 2026 and raised its diluted earnings per share estimate.</li><li>The planned spin-off of FedEx Freight into a new publicly traded company is on track for June 1, 2026, the company said.</li><li>For Q3, diluted and adjusted earnings per share for the quarter came at $5.25.</li></ul>FedEx (FDX) said on Thursday that it does not see ongoing geopolitical conflicts in the Middle East impact its operations, despite the global nature of its operations. &nbsp;“While we do not expect ongoing geopolitical conflicts between Russia and Ukraine and in the Middle East, or escalations or expansions thereof, to have a direct material effect on our business or results of operations, the broader consequences, including increased fuel prices and volatility in shipping patterns, are adversely affecting the global economy and may also have the effect of heightening other risks,” FedEx said in a filing.The company clarified the impact after <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://newsroom.fedex.com/newsroom/global-english/fedex-reports-strong-third-quarter-results">posting</a> a third-quarter (Q3) earnings beat and announcing raised guidance. Shares of the company rallied 9% after-hours at the time of writing.<h2 class="st-heading-2">Q3 Earnings</h2>FedEx Q3 revenue came in at $24 billion, compared to $22.2 billion in the corresponding quarter of fiscal 2025, and above an analyst estimate of $23.4 billion, according to data from Fiscal AI.Diluted and adjusted earnings per share for the quarter came at $5.25, up from $4.51 reported in the same quarter of last fiscal year, and above an analyst estimate of $4.07.<h2 class="st-heading-2">FY26 Outlook</h2>The company now expects 6.0% to 6.5% revenue growth rate year-over-year in fiscal 2026. It raised its diluted earnings per share estimate to $19.30 to $20.10 after excluding costs, compared to its prior forecast of $17.80 to $19.00.The company also lowered its capital spending estimate down to $4.1 billion from its older estimate of $4.5 billion.The planned spin-off of FedEx Freight into a new publicly traded company is on track for June 1, 2026, the company said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around FDX stock stayed within the ‘bullish’ territory over the past 24 hours while message volume increased from ‘low’ to ‘normal’ levels.<a href="https://stocktwits.com/symbol/FDX">FDX stock</a> has risen by 44% over the past 12 months. &nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/stellantis-customers-can-now-use-rival-tesla-supercharger-network-to-charge-cars/cZ3azo4RIhp">Stellantis Customers Can Now Use Rival Tesla Supercharger Network To Charge Cars — What’s Behind This Move?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A FedEx plane prepares to leave the FedEx Cargo Hub at Miami International Airport on February 12, 2025 in Miami, Florida.

FedEx Dismisses Direct Impact From Ongoing Tensions In Middle East But Raises Concerns On Rising Fuel Price

The company clarified the impact after posting a Q3 earnings beat and announcing raised guidance. 

Should You Buy the Vanguard S&P 500 ETF After the Recent Stock Market Sell-Off? History Offers a Crystal-Clear Answer.

Key PointsThe S&P 500 index is filled with the highest-quality companies listed on American stock exchanges...

<ul class="summary-bullets"><li>Salesforce insider trades are skewed towards sales, with CEO Marc Benioff and Slack CTO Parker Harris selling massive stakes last year.</li><li>CRM stock is under pressure amid a broader selloff in software companies’ shares over fears that AI would curtail Saas products.&nbsp;</li><li>Stocktwits sentiment for CRM has remained ‘bearish’ for two weeks.</li></ul>Salesforce, Inc. (CRM) board member David Blair Kirk purchased just over $500,000 worth of shares in the enterprise software company&nbsp;on Wednesday, marking a rare buy amid dozens of sizable insider sales and the first such purchase this year.<a href="https://stocktwits.com/symbol/CRM">CRM stock</a> posted its second straight session of losses on Wednesday, closing nearly 1% lower at $194.34. Shares further fell another 1% in extended trading.Kirk acquired 2,570 Salesforce common shares. He previously bought 1,936 shares for $500,727 in December 2025. Salesforce appointed Kirk, a former Nvidia chief scientist, to its board in July last year.&nbsp;<h2 class="st-heading-2">Large Insider Sales</h2>Kirk’s bets are an outlier amid a string of large insider sales. Salesforce CEO Marc Benioff offloaded $110 million worth of shares over 19 trades last year, according to&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.quiverquant.com/stock/CRM/insiders/">data</a> from Quiver Quant.&nbsp;Co-founder Parker Harris, who is also the CTO of Slack, sold $42 million worth of Salesforce shares in the past year, which includes the sale of a $31.5 million chunk in December.Salesforce shares traded in a narrow range for much of 2025, but have fallen sharply in 2026 as rising concerns that general-purpose AI tools could erode demand for niche enterprise software, coupled with the volatility related to the U.S.-Iran war, hammered tech stocks.CRM stock has dropped 26.6% year to date. Taking advantage of the weakness, the company earlier this week announced a $25 billion accelerated share repurchase program and said it has already received an initial delivery of about 103 million shares from financial institutions.<h2 class="st-heading-2">Retail’s View On CRM</h2>However, retail investors appear to be losing their enthusiasm. On Stocktwits, the retail sentiment for CRM has been ‘bearish’ for two weeks amid ‘low’ message volume.“$CRM not sure anyone will need this saas when there's nothing left to sell,” a retail trader&nbsp;<a href="https://stocktwits.com/VeryContent/message/647901097">said</a>, summarizing the mood. “Company gets an upgrade and doing a buyback and it keeps dropping,” another&nbsp;<a href="https://stocktwits.com/LionsFan777/message/647854273">said</a>.Last month, Salesforce forecast its fiscal 2027 revenue below Wall Street expectations on Wednesday, a signal that enterprise software demand might remain pressured.Still, 39 out of 51 analysts recommend ‘Buy’ or higher for CRM shares, 11 recommend ‘Hold’ and one suggests ‘Strong Sell,’ per Koyfin. Their average price target $273.66 implies a 41% upside to the stock’s last close.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Salesforce stock remains down more than 3% this year, weighed down by concerns over high AI-related capital expenditures and slowing sales growth projections.

Salesforce Stock Slips After-Hours: Rare Insider Buy Fails To Boost Confidence Amid AI Threat And Ongoing Selloff

Salesforce board member David Kirk acquired over $500,000 worth of shares on Wednesday 

Current Price	$601.37
Prev Close	$604.43
Open	$600.60
Dividend Yield	N/A
50-Day Moving Average	$628.39
Beta	N/A
Avg. Volume	9.59M
PE Ratio	N/A

52-Week High	$641.81
52-Week Low	$442.80
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

VOO
Vanguard S&P 500 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest VOO News

VOOVanguard S&P 500 ETF